Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis

Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple s...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychopharmacology reports Vol. 43; no. 3; pp. 382 - 390
Main Authors Khalatbari Mohseni, Golsa, Hosseini, Seyed Ahmad, Majdinasab, Nastaran, Cheraghian, Bahman
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.09.2023
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management.
AbstractList N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS-D) and anxiety (HADS-A). Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (-0.33 [-5.85-2.50] vs. 2.75 [-0.25-5.22] μmol/L; p = 0.03) and HADS-A scores (-1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS-D scores (p > 0.05). Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.
Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.
Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted. N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management.
N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).AIMN-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS-D) and anxiety (HADS-A).METHODSThis clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS-D) and anxiety (HADS-A).Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (-0.33 [-5.85-2.50] vs. 2.75 [-0.25-5.22] μmol/L; p = 0.03) and HADS-A scores (-1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS-D scores (p > 0.05).RESULTSCompared to the control group, NAC consumption significantly decreased serum MDA concentrations (-0.33 [-5.85-2.50] vs. 2.75 [-0.25-5.22] μmol/L; p = 0.03) and HADS-A scores (-1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS-D scores (p > 0.05).Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.CONCLUSIONSBased on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.
Abstract Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS). Methods This clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A). Results Compared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05). Conclusions Based on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.
N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management.
Author Cheraghian, Bahman
Majdinasab, Nastaran
Khalatbari Mohseni, Golsa
Hosseini, Seyed Ahmad
AuthorAffiliation 3 Department of Neurology, School of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
1 Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
2 Department of Nutrition, School of Allied Medical Sciences Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
4 Department of Statistics and Epidemiology, School of Public Health Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
AuthorAffiliation_xml – name: 1 Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
– name: 3 Department of Neurology, School of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
– name: 2 Department of Nutrition, School of Allied Medical Sciences Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
– name: 4 Department of Statistics and Epidemiology, School of Public Health Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
Author_xml – sequence: 1
  givenname: Golsa
  surname: Khalatbari Mohseni
  fullname: Khalatbari Mohseni, Golsa
  organization: Ahvaz Jundishapur University of Medical Sciences
– sequence: 2
  givenname: Seyed Ahmad
  orcidid: 0000-0002-9075-4126
  surname: Hosseini
  fullname: Hosseini, Seyed Ahmad
  email: seyedahmadhosseini@yahoo.com
  organization: Ahvaz Jundishapur University of Medical Sciences
– sequence: 3
  givenname: Nastaran
  surname: Majdinasab
  fullname: Majdinasab, Nastaran
  organization: Ahvaz Jundishapur University of Medical Sciences
– sequence: 4
  givenname: Bahman
  surname: Cheraghian
  fullname: Cheraghian, Bahman
  organization: Ahvaz Jundishapur University of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37386885$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAQgCNUREvphQdAlrgg1C3-SezkhFDVQqWqIAQSN8txJq2XxA62t-3eKp6AZ-RJmO2Wqq0QByuJ883nmfE8LTZ88FAUzxndY5TyN36KfI9xIemjYotXqpwxJb5t3HnfLHZSmlOEV0uUT4pNoUQt67raKn4e9D3YnEjoycnvq1_GQl4OdpkyOA8keBIuXWeyOweScoSUSOvCaOJ3iGmXdDCt9lzwu8T4DtelQwFJy3HKYUzEeTJhNHg84sLlMzIuhuymAW12gBiSS8-Kx70ZEuzcPLeLr4cHX_Y_zI4_vj_af3c8s5JKOuMgem4MbxvZ866l0tSUdqKp8ZPWFZOgWlappu-kVI0xqjIWgQrKsmemAbFdHK29XTBzPUWHVSx1ME5fb4R4qk3MDtPS0Cjgqmpow01phDVtbbCfHWOmli1j6Hq7dk2LdoTOYn3RDPek9_94d6ZPw7lmtGwkrRUaXt0YYvixgJT16JKFYTAewiJpXgs8UVWSIvryAToPi-ixV0hJoZgoaYXUi7sp3eby964ReL0GLLY9RehvEUb1apb0apb09SwhTB_A1mW8yLAqxw3_DmHrkAs3wPI_cn3y6TNfx_wBNdTefQ
CitedBy_id crossref_primary_10_1016_j_heliyon_2024_e40097
crossref_primary_10_1002_jdn_10392
crossref_primary_10_1016_j_canlet_2024_217405
crossref_primary_10_1007_s00702_024_02792_0
crossref_primary_10_3390_biom14101266
crossref_primary_10_3390_jpm14050488
crossref_primary_10_1016_j_genhosppsych_2024_10_018
crossref_primary_10_3390_ijms252011024
crossref_primary_10_1038_s41598_023_39668_4
crossref_primary_10_1016_j_heliyon_2024_e26271
crossref_primary_10_1016_j_pharmthera_2025_108825
crossref_primary_10_3390_psychiatryint6010034
crossref_primary_10_1007_s12031_025_02332_9
crossref_primary_10_1515_revneuro_2023_0091
Cites_doi 10.1016/j.redox.2015.07.012
10.1097/00007890-200003150-00001
10.3390/nu4101399
10.1177/1756286418819074
10.1007/s00277-011-1404-z
10.1017/S1461145707008401
10.1002/brb3.208
10.1006/niox.2001.0356
10.32598/CJNS.8.29.4
10.1191/1352458505ms1240oa
10.1097/WNF.0000000000000090
10.4314/tjpr.v10i2.66554
10.2174/1871523011312030003
10.7224/1537-2073.2013-013
10.1590/S1516-44462011000400011
10.1016/j.bbagen.2013.04.016
10.1179/1351000211Y.0000000007
10.1186/1477-7525-1-1
10.1016/S1474-4422(02)00102-3
10.1155/2017/3175358
10.1016/j.mehy.2012.03.021
10.1523/JNEUROSCI.21-10-03322.2001
10.1186/1471-244X-13-196
10.4103/0974-7753.100090
10.5414/CNP59441
10.2174/1570159X11666131120223530
10.1002/ana.20736
10.1371/journal.pone.0054163
10.1016/j.jad.2011.06.005
10.1016/j.jns.2008.06.029
10.1001/archgenpsychiatry.2009.60
10.1177/1352458520970841
10.1016/j.bbadis.2010.06.011
10.1199/tab.0142
10.1016/j.pnpbp.2009.01.001
10.1089/cap.2012.0066
10.1503/jpn.100057
10.1016/j.clinbiochem.2011.09.021
10.1155/2012/240146
10.1016/S0753-3322(00)88859-9
10.1159/000306591
10.3109/00207454.2013.801844
10.1016/j.msard.2017.11.003
10.1016/j.clinbiochem.2012.01.023
10.1080/10715762.2018.1468564
10.1002/jnr.10408
10.1016/S0376-8716(99)00040-X
10.1371/journal.pone.0065184
10.1586/ern.10.7
10.1155/2012/609421
10.1016/j.tips.2013.01.001
10.1089/152308602753625988
10.1016/j.jns.2012.07.045
10.1159/000355040
10.1016/j.biopsych.2008.04.022
10.1016/j.jad.2010.08.001
10.1016/j.bbagen.2012.11.016
10.1186/1740-2557-2-4
10.2147/NDT.S241497
10.1093/jn/138.10.1872
10.1186/1471-2377-13-128
ContentType Journal Article
Copyright 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
– notice: 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
– notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
7X8
5PM
DOA
DOI 10.1002/npr2.12360
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Psychology
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
Publicly Available Content Database

MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access (WRLC)
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Khalatbari Mohseni et al
EISSN 2574-173X
EndPage 390
ExternalDocumentID oai_doaj_org_article_e97e2759092a4a3cab8a257d11a86b11
PMC10496087
37386885
10_1002_npr2_12360
NPR212360
Genre researchArticle
Journal Article
GeographicLocations Iran
Switzerland
GeographicLocations_xml – name: Switzerland
– name: Iran
GrantInformation_xml – fundername: Ahvaz Jundishapur University of Medical Sciences
  funderid: NRC‐9625
– fundername: Ahvaz Jundishapur University of Medical Sciences
  grantid: NRC-9625
– fundername: ;
  grantid: NRC‐9625
GroupedDBID 0R~
1OC
24P
7X7
8FI
8FJ
AAMMB
ABDBF
ABUWG
ACCMX
ACGFS
ACUHS
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
AEFGJ
AFKRA
AGXDD
AIDQK
AIDYY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
EBS
EJD
FYUFA
GROUPED_DOAJ
HMCUK
IAO
IHR
INH
IPY
ITC
M~E
O9-
OK1
OVD
OVEED
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSYQQ
RPM
TEORI
UKHRP
WIN
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
ALIPV
CITATION
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c6060-2e3f2aa2b96f2db06a800d3986f208516e7b1579fd6679aa75ac00d5e44f1a9e3
IEDL.DBID 24P
ISSN 2574-173X
IngestDate Wed Aug 27 01:30:13 EDT 2025
Thu Aug 21 18:36:24 EDT 2025
Fri Jul 11 03:40:21 EDT 2025
Wed Aug 13 07:48:14 EDT 2025
Wed Feb 19 02:22:55 EST 2025
Tue Jul 01 03:07:52 EDT 2025
Thu Apr 24 23:00:00 EDT 2025
Wed Aug 20 07:27:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords anxiety
antioxidant
glutathione
multiple sclerosis
depression
oxidative stress
N-acetylcysteine
Language English
License Attribution-NonCommercial-NoDerivs
2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c6060-2e3f2aa2b96f2db06a800d3986f208516e7b1579fd6679aa75ac00d5e44f1a9e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-9075-4126
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fnpr2.12360
PMID 37386885
PQID 2863713405
PQPubID 4378887
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_e97e2759092a4a3cab8a257d11a86b11
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10496087
proquest_miscellaneous_2832577560
proquest_journals_2863713405
pubmed_primary_37386885
crossref_primary_10_1002_npr2_12360
crossref_citationtrail_10_1002_npr2_12360
wiley_primary_10_1002_npr2_12360_NPR212360
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2023
PublicationDateYYYYMMDD 2023-09-01
PublicationDate_xml – month: 09
  year: 2023
  text: September 2023
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Neuropsychopharmacology reports
PublicationTitleAlternate Neuropsychopharmacol Rep
PublicationYear 2023
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2010; 10
2012; 2012
2015; 38
2012; 321
2010; 14
2017; 4
2019; 12
2013; 123
2020; 16
2003; 59
2011; 10
2011; 15
2013; 8
2007; 32
2011; 16
2014; 21
2010; 61
2014; 4
2011; 129
2013; 13
2013; 12
2000; 54
2014; 16
1999; 57
2003; 1
2008; 64
2008; 274
2012; 22
2014; 12
2009; 66
2011; 135
2015; 6
2013; 1830
2017; 2017
2000; 69
2006; 59
2002; 1
2011; 33
2002; 4
2008; 11
2011; 36
2012; 79
2011; 9
2001; 21
2018; 19
2009; 33
2012; 91
2001; 5
2013; 34
2022; 8
2020; 26
2002; 70
2011; 1812
2008; 138
2018; 52
2005; 2
2012; 45
2012; 4
2009; 109
2005; 11
e_1_2_12_4_1
e_1_2_12_6_1
e_1_2_12_19_1
Hara Y (e_1_2_12_47_1) 2017; 4
e_1_2_12_2_1
e_1_2_12_38_1
e_1_2_12_20_1
e_1_2_12_41_1
e_1_2_12_66_1
Krotenko N (e_1_2_12_17_1) 2009; 109
e_1_2_12_43_1
e_1_2_12_64_1
e_1_2_12_24_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_62_1
e_1_2_12_60_1
Bulut M (e_1_2_12_22_1) 2007; 32
e_1_2_12_28_1
e_1_2_12_49_1
e_1_2_12_31_1
e_1_2_12_52_1
e_1_2_12_33_1
e_1_2_12_35_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_58_1
e_1_2_12_14_1
e_1_2_12_12_1
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_50_1
e_1_2_12_3_1
e_1_2_12_5_1
e_1_2_12_18_1
e_1_2_12_16_1
e_1_2_12_39_1
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
e_1_2_12_61_1
e_1_2_12_40_1
Atakisi O (e_1_2_12_54_1) 2010; 14
e_1_2_12_27_1
e_1_2_12_29_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_34_1
Bayır A (e_1_2_12_57_1) 2011; 15
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_15_1
e_1_2_12_13_1
e_1_2_12_11_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_9_1
References_xml – volume: 69
  start-page: 703
  issue: 5
  year: 2000
  end-page: 4
  article-title: N‐acetylcysteine: not simply a glutathione precusor
  publication-title: Transplantation
– volume: 26
  start-page: 1816
  issue: 14
  year: 2020
  end-page: 21
  article-title: Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS
  publication-title: Mult Scler J
– volume: 123
  start-page: 776
  issue: 11
  year: 2013
  end-page: 82
  article-title: Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing‐remitting multiple sclerosis
  publication-title: Int J Neurosci
– volume: 274
  start-page: 48
  issue: 1–2
  year: 2008
  end-page: 53
  article-title: Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity
  publication-title: J Neurol Sci
– volume: 21
  start-page: 13
  issue: 1
  year: 2014
  end-page: 20
  article-title: Glutathione homeostasis disruption of erythrocytes, but not glutathione peroxidase activity change, is closely accompanied with neurological and radiological scoring of acute CNS inflammation
  publication-title: Neuroimmunomodulation
– volume: 45
  start-page: 440
  issue: 6
  year: 2012
  end-page: 4
  article-title: Peripheral oxidative stress in relapsing–remitting multiple sclerosis
  publication-title: Clin Biochem
– volume: 2012
  start-page: 1
  year: 2012
  end-page: 13
  article-title: Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder
  publication-title: Oxid Med Cell Longev
– volume: 4
  start-page: 108
  issue: 2
  year: 2014
  end-page: 22
  article-title: N‐acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities
  publication-title: Brain Behav
– volume: 34
  start-page: 167
  issue: 3
  year: 2013
  end-page: 77
  article-title: The promise of N‐acetylcysteine in neuropsychiatry
  publication-title: Trends Pharmacol Sci
– volume: 10
  start-page: 141
  year: 2011
  end-page: 6
  article-title: Pharmacodynamic effect of N‐acetylcysteine as adjunctive therapy in mild systemic lupus erythematosus patients
  publication-title: Trop J Pharm Res
– volume: 2012
  start-page: 1
  year: 2012
  end-page: 12
  article-title: Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems
  publication-title: Oxid Med Cell Longev
– volume: 16
  start-page: 1265
  year: 2020
  end-page: 78
  article-title: Evidence for a beneficial effect of oral N‐acetylcysteine on functional outcomes and inflammatory biomarkers in patients with acute ischemic stroke
  publication-title: Neuropsychiatr Dis Treat
– volume: 70
  start-page: 580
  issue: 4
  year: 2002
  end-page: 7
  article-title: Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S‐nitrosothiols and with changes in glutathione levels
  publication-title: J Neurosci Res
– volume: 13
  start-page: 1
  issue: 1
  year: 2013
  end-page: 13
  article-title: Incidence and prevalence of multiple sclerosis in Europe: a systematic review
  publication-title: BMC Neurol
– volume: 36
  start-page: 78
  issue: 2
  year: 2011
  end-page: 86
  article-title: N‐acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
  publication-title: J Psychiatry Neurosci
– volume: 64
  start-page: 468
  issue: 6
  year: 2008
  end-page: 75
  article-title: N‐acetyl cysteine for depressive symptoms in bipolar disorder—a double‐blind randomized placebo‐controlled trial
  publication-title: Biol Psychiatry
– volume: 135
  start-page: 389
  issue: 1–3
  year: 2011
  end-page: 94
  article-title: The efficacy of N‐acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial
  publication-title: J Affect Disord
– volume: 2017
  start-page: 1
  year: 2017
  end-page: 9
  article-title: Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States
  publication-title: Mult Scler Int
– volume: 2
  start-page: 4
  issue: 1
  year: 2005
  article-title: N‐acetyl‐L‐cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats
  publication-title: J Autoimmune Dis
– volume: 8
  start-page: 104
  issue: 2
  year: 2022
  end-page: 16
  article-title: The time‐trend of multiple sclerosis incidence and prevalence in Khuzestan Province, Iran
  publication-title: Caspian J Neurol Sci
– volume: 32
  start-page: 435
  issue: 6
  year: 2007
  end-page: 8
  article-title: Malondialdehyde levels in adult attention‐deficit hyperactivity disorder
  publication-title: J Psychiatry Neurosci
– volume: 59
  start-page: 441
  issue: 6
  year: 2003
  end-page: 6
  article-title: N‐acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients–a pilot study
  publication-title: Clin Nephrol
– volume: 109
  start-page: 53
  issue: 7 Suppl 2
  year: 2009
  end-page: 6
  article-title: Parameters of antioxidant protection in multiple sclerosis
  publication-title: Zh Nevrol Psikhiatr Im S S Korsakova
– volume: 11
  start-page: 851
  issue: 6
  year: 2008
  end-page: 76
  article-title: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
  publication-title: Int J Neuropsychopharmacol
– volume: 16
  start-page: 166
  issue: 4
  year: 2011
  end-page: 72
  article-title: Aminoguanidine and N‐acetyl‐cysteine supress oxidative and nitrosative stress in EAE rat brains
  publication-title: Redox Rep
– volume: 52
  start-page: 751
  issue: 7
  year: 2018
  end-page: 62
  article-title: N‐acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why
  publication-title: Free Radic Res
– volume: 8
  issue: 6
  year: 2013
  article-title: Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis
  publication-title: PLoS One
– volume: 138
  start-page: 1872
  issue: 10
  year: 2008
  end-page: 9
  article-title: N‐acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis
  publication-title: J Nutr
– volume: 13
  start-page: 1
  issue: 1
  year: 2013
  end-page: 7
  article-title: A randomized double blind placebo controlled clinical trial of N‐acetylcysteine added to risperidone for treating autistic disorders
  publication-title: BMC Psychiatry
– volume: 4
  start-page: 201
  issue: 3
  year: 2017
  end-page: 6
  article-title: Evaluation of the neuroprotective potential of N‐acetylcysteine for prevention and treatment of cognitive aging and dementia
  publication-title: J Prev Alzheimers Dis
– volume: 66
  start-page: 756
  issue: 7
  year: 2009
  end-page: 63
  article-title: N‐acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double‐blind, placebo‐controlled study
  publication-title: Arch Gen Psychiatry
– volume: 1830
  start-page: 3350
  issue: 5
  year: 2013
  end-page: 3
  article-title: Glutathione and glutathione analogues; therapeutic potentials
  publication-title: Biochim Biophys Acta
– volume: 4
  start-page: 176
  issue: 3
  year: 2012
  end-page: 8
  article-title: N‐acetylcysteine in the treatment of trichotillomania
  publication-title: Int J Trichology
– volume: 45
  start-page: 26
  issue: 1–2
  year: 2012
  end-page: 30
  article-title: Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis
  publication-title: Clin Biochem
– volume: 1
  start-page: 232
  issue: 4
  year: 2002
  end-page: 41
  article-title: The role of nitric oxide in multiple sclerosis
  publication-title: Lancet Neurol
– volume: 14
  start-page: 19
  issue: 1
  year: 2010
  end-page: 23
  article-title: Effects of reduced glutathione on nitric oxide level, total antioxidant and oxidant capacity and adenosine deaminase activity
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 4
  start-page: 1399
  issue: 10
  year: 2012
  end-page: 440
  article-title: Dysregulation of glutathione homeostasis in neurodegenerative diseases
  publication-title: Nutrients
– volume: 12
  start-page: 193
  issue: 2
  year: 2014
  end-page: 204
  article-title: Oxidative imbalance and anxiety disorders
  publication-title: Curr Neuropharmacol
– volume: 8
  issue: 1
  year: 2013
  article-title: Amelioration of acute sequelae of blast induced mild traumatic brain injury by N‐acetyl cysteine: a double‐blind, placebo controlled study
  publication-title: PLoS One
– volume: 12
  start-page: 223
  issue: 3
  year: 2013
  end-page: 8
  article-title: N‐acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial
  publication-title: Antiinflamm Antiallergy Agents Med Chem
– volume: 12
  year: 2019
  article-title: Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon‐β1a‐treated multiple sclerosis
  publication-title: Ther Adv Neurol Disord
– volume: 19
  start-page: 35
  year: 2018
  end-page: 9
  article-title: The prevalence of anxiety and associated factors in persons with multiple sclerosis
  publication-title: Mult Scler Relat Disord
– volume: 1812
  start-page: 141
  issue: 2
  year: 2011
  end-page: 50
  article-title: Radical changes in multiple sclerosis pathogenesis
  publication-title: Biochim Biophys Acta
– volume: 21
  start-page: 3322
  issue: 10
  year: 2001
  end-page: 31
  article-title: Pyruvate released by astrocytes protects neurons from copper‐catalyzed cysteine neurotoxicity
  publication-title: J Neurosci
– volume: 5
  start-page: 349
  issue: 4
  year: 2001
  end-page: 60
  article-title: N‐acetylcysteine inhibits in vivo nitric oxide production by inducible nitric oxide synthase
  publication-title: Nitric Oxide
– volume: 91
  start-page: 1097
  issue: 7
  year: 2012
  end-page: 105
  article-title: N‐acetylcysteine reduces oxidative stress in sickle cell patients
  publication-title: Ann Hematol
– volume: 9
  year: 2011
  article-title: Glutathione
  publication-title: Arabidopsis Book
– volume: 79
  start-page: 8
  issue: 1
  year: 2012
  end-page: 12
  article-title: N‐acetyl‐cysteine in the treatment of Parkinson's disease. What are we waiting for?
  publication-title: Med Hypotheses
– volume: 1830
  start-page: 4117
  issue: 8
  year: 2013
  end-page: 29
  article-title: The chemistry and biological activities of N‐acetylcysteine
  publication-title: Biochim Biophys Acta
– volume: 321
  start-page: 49
  issue: 1–2
  year: 2012
  end-page: 53
  article-title: Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale
  publication-title: J Neurol Sci
– volume: 38
  start-page: 127
  issue: 4
  year: 2015
  end-page: 31
  article-title: Tolerability and safety of combined glatiramer acetate and N‐acetylcysteine in relapsing‐remitting multiple sclerosis
  publication-title: Clin Neuropharmacol
– volume: 33
  start-page: 363
  issue: 2
  year: 2009
  end-page: 6
  article-title: Correlation between lipid peroxidation‐induced TBARS level and disease severity in obsessive–compulsive disorder
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
– volume: 54
  start-page: 100
  issue: 2
  year: 2000
  end-page: 2
  article-title: Epidemiologic studies of multiple sclerosis: a review
  publication-title: Biomed Pharmacother
– volume: 16
  start-page: 105
  issue: 2
  year: 2014
  end-page: 9
  article-title: Validation of mood measures for people with multiple sclerosis
  publication-title: Int J MS Care
– volume: 57
  start-page: 61
  issue: 1
  year: 1999
  end-page: 7
  article-title: Protective effect of N‐acetylcysteine on reduced glutathione, reduced glutathione‐related enzymes and lipid peroxidation in methanol intoxication
  publication-title: Drug Alcohol Depend
– volume: 15
  start-page: 1
  issue: 1
  year: 2011
  end-page: 190
  article-title: Effects of N‐acetylcysteine on the erythrocyte and liver cholinesterase, nitric oxide and malondialdehyde levels in acute organophosphate toxicity
  publication-title: Crit Care
– volume: 6
  start-page: 198
  year: 2015
  end-page: 205
  article-title: Effects of N‐acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study
  publication-title: Redox Biol
– volume: 129
  start-page: 317
  issue: 1–3
  year: 2011
  end-page: 20
  article-title: N‐acetyl cysteine add‐on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo‐controlled trial
  publication-title: J Affect Disord
– volume: 11
  start-page: 677
  issue: 6
  year: 2005
  end-page: 82
  article-title: Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity
  publication-title: Mult Scler J
– volume: 10
  start-page: 421
  issue: 3
  year: 2010
  end-page: 40
  article-title: Environmental risk factors in multiple sclerosis
  publication-title: Expert Rev Neurother
– volume: 4
  start-page: 221
  issue: 1
  year: 2002
  end-page: 6
  article-title: N‐acetylcysteine negatively modulates nitric oxide production in endotoxin‐treated rats through inhibition of NF‐κB activation
  publication-title: Antioxid Redox Signal
– volume: 59
  start-page: 478
  issue: 3
  year: 2006
  end-page: 89
  article-title: Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
  publication-title: Ann Neurol
– volume: 22
  start-page: 472
  issue: 6
  year: 2012
  end-page: 3
  article-title: Treatment with adjunctive N‐acetylcysteine in an adolescent with selective serotonin reuptake inhibitor‐resistant anxiety
  publication-title: J Child Adolesc Psychopharmacol
– volume: 1
  start-page: 1
  issue: 1
  year: 2003
  end-page: 5
  article-title: The hospital anxiety and depression scale (HADS): translation and validation study of the Iranian version
  publication-title: Health Qual Life Outcomes
– volume: 61
  start-page: 210
  issue: 4
  year: 2010
  end-page: 4
  article-title: Relationship of possible stress‐related biochemical markers to oxidative/antioxidative status in obsessive‐compulsive disorder
  publication-title: Neuropsychobiology
– volume: 33
  start-page: 374
  issue: 4
  year: 2011
  end-page: 8
  article-title: N‐acetylcysteine for major depressive episodes in bipolar disorder = N‐acetilcisteína para o tratamento de episódios de depressão maior no transtorno bipolar
  publication-title: Braz J Psychiatry
– ident: e_1_2_12_50_1
  doi: 10.1016/j.redox.2015.07.012
– ident: e_1_2_12_51_1
  doi: 10.1097/00007890-200003150-00001
– ident: e_1_2_12_16_1
  doi: 10.3390/nu4101399
– volume: 4
  start-page: 201
  issue: 3
  year: 2017
  ident: e_1_2_12_47_1
  article-title: Evaluation of the neuroprotective potential of N‐acetylcysteine for prevention and treatment of cognitive aging and dementia
  publication-title: J Prev Alzheimers Dis
– ident: e_1_2_12_67_1
  doi: 10.1177/1756286418819074
– ident: e_1_2_12_38_1
  doi: 10.1007/s00277-011-1404-z
– ident: e_1_2_12_19_1
  doi: 10.1017/S1461145707008401
– ident: e_1_2_12_35_1
  doi: 10.1002/brb3.208
– ident: e_1_2_12_55_1
  doi: 10.1006/niox.2001.0356
– ident: e_1_2_12_9_1
  doi: 10.32598/CJNS.8.29.4
– ident: e_1_2_12_12_1
  doi: 10.1191/1352458505ms1240oa
– ident: e_1_2_12_39_1
  doi: 10.1097/WNF.0000000000000090
– ident: e_1_2_12_43_1
  doi: 10.4314/tjpr.v10i2.66554
– ident: e_1_2_12_59_1
  doi: 10.2174/1871523011312030003
– ident: e_1_2_12_40_1
  doi: 10.7224/1537-2073.2013-013
– ident: e_1_2_12_65_1
  doi: 10.1590/S1516-44462011000400011
– ident: e_1_2_12_31_1
  doi: 10.1016/j.bbagen.2013.04.016
– ident: e_1_2_12_32_1
  doi: 10.1179/1351000211Y.0000000007
– ident: e_1_2_12_41_1
  doi: 10.1186/1477-7525-1-1
– ident: e_1_2_12_53_1
  doi: 10.1016/S1474-4422(02)00102-3
– ident: e_1_2_12_11_1
  doi: 10.1155/2017/3175358
– ident: e_1_2_12_49_1
  doi: 10.1016/j.mehy.2012.03.021
– ident: e_1_2_12_48_1
  doi: 10.1523/JNEUROSCI.21-10-03322.2001
– volume: 14
  start-page: 19
  issue: 1
  year: 2010
  ident: e_1_2_12_54_1
  article-title: Effects of reduced glutathione on nitric oxide level, total antioxidant and oxidant capacity and adenosine deaminase activity
  publication-title: Eur Rev Med Pharmacol Sci
– ident: e_1_2_12_60_1
  doi: 10.1186/1471-244X-13-196
– ident: e_1_2_12_62_1
  doi: 10.4103/0974-7753.100090
– ident: e_1_2_12_45_1
  doi: 10.5414/CNP59441
– volume: 32
  start-page: 435
  issue: 6
  year: 2007
  ident: e_1_2_12_22_1
  article-title: Malondialdehyde levels in adult attention‐deficit hyperactivity disorder
  publication-title: J Psychiatry Neurosci
– ident: e_1_2_12_21_1
  doi: 10.2174/1570159X11666131120223530
– ident: e_1_2_12_25_1
  doi: 10.1002/ana.20736
– ident: e_1_2_12_34_1
  doi: 10.1371/journal.pone.0054163
– ident: e_1_2_12_63_1
  doi: 10.1016/j.jad.2011.06.005
– ident: e_1_2_12_3_1
  doi: 10.1016/j.jns.2008.06.029
– ident: e_1_2_12_61_1
  doi: 10.1001/archgenpsychiatry.2009.60
– ident: e_1_2_12_8_1
  doi: 10.1177/1352458520970841
– ident: e_1_2_12_26_1
  doi: 10.1016/j.bbadis.2010.06.011
– ident: e_1_2_12_29_1
  doi: 10.1199/tab.0142
– ident: e_1_2_12_23_1
  doi: 10.1016/j.pnpbp.2009.01.001
– volume: 15
  start-page: 1
  issue: 1
  year: 2011
  ident: e_1_2_12_57_1
  article-title: Effects of N‐acetylcysteine on the erythrocyte and liver cholinesterase, nitric oxide and malondialdehyde levels in acute organophosphate toxicity
  publication-title: Crit Care
– ident: e_1_2_12_58_1
  doi: 10.1089/cap.2012.0066
– ident: e_1_2_12_37_1
  doi: 10.1503/jpn.100057
– ident: e_1_2_12_4_1
  doi: 10.1016/j.clinbiochem.2011.09.021
– ident: e_1_2_12_27_1
  doi: 10.1155/2012/240146
– ident: e_1_2_12_5_1
  doi: 10.1016/S0753-3322(00)88859-9
– ident: e_1_2_12_24_1
  doi: 10.1159/000306591
– ident: e_1_2_12_42_1
  doi: 10.3109/00207454.2013.801844
– ident: e_1_2_12_10_1
  doi: 10.1016/j.msard.2017.11.003
– ident: e_1_2_12_14_1
  doi: 10.1016/j.clinbiochem.2012.01.023
– ident: e_1_2_12_52_1
  doi: 10.1080/10715762.2018.1468564
– ident: e_1_2_12_15_1
  doi: 10.1002/jnr.10408
– ident: e_1_2_12_44_1
  doi: 10.1016/S0376-8716(99)00040-X
– ident: e_1_2_12_2_1
  doi: 10.1371/journal.pone.0065184
– ident: e_1_2_12_6_1
  doi: 10.1586/ern.10.7
– ident: e_1_2_12_20_1
  doi: 10.1155/2012/609421
– ident: e_1_2_12_36_1
  doi: 10.1016/j.tips.2013.01.001
– ident: e_1_2_12_56_1
  doi: 10.1089/152308602753625988
– ident: e_1_2_12_13_1
  doi: 10.1016/j.jns.2012.07.045
– ident: e_1_2_12_18_1
  doi: 10.1159/000355040
– ident: e_1_2_12_64_1
  doi: 10.1016/j.biopsych.2008.04.022
– ident: e_1_2_12_66_1
  doi: 10.1016/j.jad.2010.08.001
– ident: e_1_2_12_28_1
  doi: 10.1016/j.bbagen.2012.11.016
– ident: e_1_2_12_33_1
  doi: 10.1186/1740-2557-2-4
– ident: e_1_2_12_46_1
  doi: 10.2147/NDT.S241497
– volume: 109
  start-page: 53
  issue: 7
  year: 2009
  ident: e_1_2_12_17_1
  article-title: Parameters of antioxidant protection in multiple sclerosis
  publication-title: Zh Nevrol Psikhiatr Im S S Korsakova
– ident: e_1_2_12_30_1
  doi: 10.1093/jn/138.10.1872
– ident: e_1_2_12_7_1
  doi: 10.1186/1471-2377-13-128
SSID ssj0002000234
Score 2.3513799
Snippet Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric...
N-acetylcysteine (NAC), a thiol-containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric...
Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric...
N‐acetylcysteine (NAC) supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in multiple sclerosis (MS) patients. The...
Abstract Aim N‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 382
SubjectTerms antioxidant
Antioxidants
Anxiety
Biomarkers
Blood
Brain research
Chronic illnesses
depression
Disease
Drug dosages
Glutathione
Lipid peroxidation
Mental depression
Multiple sclerosis
Neurological disorders
N‐acetylcysteine
Obsessive compulsive disorder
Original
Oxidative stress
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K3902LSotgZZ1Y8uyHse2NIRCl6UkkJuRLIluSORlvYHsreQX5Df2l3QkeZ1dGtpLDzZ-jMVIGjEz1sw3CL0tSxoKv5mMcJNnoG9Jpp2FU0Ed5aVmTods5G8TdnhMv55UJxulvkJMWIIHTgO3byW3hFcyl0RRVTZKCwViZopCCaZTVi_ovA1n6jRurwVlRAc8UrLv5wvyIUCN5FsaKAL132Zd_hkkuWm8Ru1zcB_d681G_DGx-wDdsf4h2psm3OnVGB_dpFF1Y7yHpzeI1KtH6CphFHe4dXjy6-e1auxyddYEEGcwMnHrcXs5MxECHKfkERzS8kPkzgKaG6Jl_Rgrb-C4DJGeuFudz5fteYdnHvf4rB0OP3bxOkwRd8AtjMKse4yOD74cfT7M-uILWQM-TZ4RWzqiFNGSOWJ0zhSYlqaUAm6DmcYs10XFpTOMcakUr1QDBJWl1BVK2vIJ2vGtt88QNsLxiglXUXB_pMmlzitw1GRIgKBK6hF6t56QuumRyUOBjLM6YSqTOkxeHSdvhN4MtPOEx3Er1acwrwNFwNCOD0Cy6l6y6n9J1gjtrqWi7hd2VxPBypB-m1cj9Hp4DUsy7LMob9uLQFNCO9Bl4ONpEqKBkwAkxYSAr8WWeG2xuv3Gz35E2G9wnMHdFHyE3kdJ_Ev_68n0O4lXz__HSLxAdwkspxRat4t2losL-xJssaV-FZfdbzhDNG4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vvgi1s_YKitKQbnYZLPZjydRsRTB45AW7i3sZjf1oE3OyxV6b-Jf4N_oX-LMJpfzsPQhIR-TsJuZ2Z3ZzPyGkNdZxrHwm4uZdEkM8y2LbeVhl_KKy8yKymI28texOD7lX6b5tF9wa_uwyvWYGAZq15S4Rn7IlMgw7zHJ389_xFg1Cv-u9iU0bpM7CF2GIV1yKoc1FhbgXPiASsoO6_mCvUPAkWRrHgpw_dfZmP-HSv5rwoY56Og-udcbj_RDx-1dcsvXD8jBpEOfXo3oySaZqh3RAzrZ4FKvHpJfHVJxS5uKjv_8_G1Kv1ydlwjlDKYmbWraXM1cAAKnXQoJxeR8jN9ZwOuGmNl6RE3tYLvCeE_ari7my-aipbOa9iitLcXlXboOVqQttBa-wqx9RE6PPp98Oo77EgxxCZ5NEjOfVcwYZrWomLOJMGBgukwrOEVjTXhp01zqygkhtTEyNyUQ5J7zKjXaZ4_JTt3U_imhTlUyF6rKOThB2iXaJjm4axrTILjRNiJv1gwpyh6fHMtknBcdsjIrkHlFYF5EXg208w6V41qqj8jXgQKRtMOFZnFW9IpZeC09k7lONDPcZKWxysAw5tLUKGHTNCL7a6koevVui40wRuTlcBsUE_-2mNo3l0iTwXugy9COJ50QDS1BOCmhFDyttsRrq6nbd-rZ9wD-De4zOJ1KRuRtkMQb-l-MJ99YOHp2cyf2yF0GitKFzu2TneXi0j8HW2tpXwSF-gtfLSxB
  priority: 102
  providerName: ProQuest
Title Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fnpr2.12360
https://www.ncbi.nlm.nih.gov/pubmed/37386885
https://www.proquest.com/docview/2863713405
https://www.proquest.com/docview/2832577560
https://pubmed.ncbi.nlm.nih.gov/PMC10496087
https://doaj.org/article/e97e2759092a4a3cab8a257d11a86b11
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3da9swEMBFaV_2Mva9bG3Q2ChsxKsty_qAvTRbQxkshNFC3oxky12gtUOcQvNW9hfsb9xfsjvZcRpWBnuI8-GTka276E6--5mQd3HM8cFvecBkHgYw37LAFg42ES-4jK0oLFYjfxuL03P-dZpMd8indS1Mw4foFtzQMvz_NRq4sfXRHWjofME-IjsEAvY9rK1Fcj7jk26FhXmYC95WBrXkQSTjaccnZUeb5lszkgf33-dt_p00edeZ9bPR6BF52LqR9LgZ98dkx5VPyOGk4VCvBvRsU1ZVD-ghnWwI1aun5GfDLK5pVdDx79tfJnPL1WWGUGe4LLQqaXUzyz0SnDbFJBTL9DGTZwGH67JnywE1ZQ6vG8z8pPXqar6srmo6K2nLa60pLvTSddoiraG3cBVm9TNyPjo5-3watA9jCDKIccKAubhgxjCrRcFyGwoDrmYeawVf0W0TTtookbrIhZDaGJmYDAQSx3kRGe3i52S3rEr3ktBcFTIRqkg4hEM6D7UNEwjcNBZEcKNtj7xfD0iataRyfGDGZdowllmKg5f6weuRt53svOFz3Cs1xHHtJJCp7X-oFhdpa6Kp09IxmehQM8NNnBmrDGhOHkVGCRtFPbK_1oq0NfQ6ZUrEWI4bJj3yptsNJor3XUzpqmuUieE4cMrQjxeNEnU9QbCUUApaqy312urq9p5y9sNjwCGQhvBTyR754DXxH-efjiffmf_06n-EX5MHDEyoSanbJ7vLxbU7AB9safve1GArp7JP9o6HX4YjeB-eQNu-X9f4A2oCM_E
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdG9wAviP8UBhgBk0ANSxzHiR8QYrCpY1tVoU7aW7BjZ6u0JaXpxPqG-AR8Ej4Un4S7_CsV0972kCptLpbdO5_v7LvfEfLS9zkWfjMOC43rwHrLHJ1a-PB4ykNfi1RjNvL-QPQP-OfD4HCF_G5yYTCsstGJpaI2eYJ75BssEj7mPbrB-8k3B6tG4elqU0KjEotdO_8OLlvxbucT8PcVY9tbo499p64q4CRgrLsOs37KlGJaipQZ7QoFNpPxZQRf0f4QNtReEMrUCBFKpcJAJUAQWM5TT0nrQ7vXyCr3wZXpkNXNrcHwS7urw0oAGd7ioLKNbDJlbxHixF1a-coCARdZtf8HZ_5rNJer3vYtcrM2V-mHSr5ukxWb3SHrwwrvet6jo0X6VtGj63S4QMKe3yU_K2zkguYpHfz58UsldjY_SRA8Goxbmmc0Px-bEnqcVkkrFOEAMGJoCs21UbpZj6rMwHWOEaa0mJ9OZvlpQccZrXFhC4obyrQJj6QF9Bb-hXFxjxxcCXvuk06WZ_YhoSZKw0BEacDB7ZLGldoNwEGUmHjBldRd8rphSJzUiOhYmOMkrrCcWYzMi0vmdcmLlnZS4YBcSLWJfG0pELu7_CGfHsW1KoitDC0LA-lKprjyE6UjBYrTeJ6KhPa8LllrpCKuFUoRL8S_S563j0EV4PmOymx-hjQ-tANDhn48qISo7QkCWIkogrejJfFa6uryk2x8XMKNg8MObm4UdsmbUhIvGX8Mc4GVd48uH8Qzcr0_2t-L93YGu4_JDQaTpgrcWyOd2fTMPgFLb6af1tOLkq9XPaP_AtQ3acA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkBAviP8UBhgBk0ANTZzEjh8QAsa0MagqtEl9C3ZsQ6UtKU0n1jfEJ-Dz8HH4JNzlX6mY9raHVm1zsezeH985d78j5EkYRtj4zXhMGN-D_ZZ52ll4CyIXiVBzp7Ea-eOQ7xxE78fxeI38bmthMK2ytYmVoTZFhmfkA5bwEOse_XjgmrSI0db2q-k3DztI4ZPWtp1GLSJ7dvEdwrfy5e4W8PopY9vv9t_ueE2HAS8Dx933mA0dU4ppyR0z2ucK_CcTygS-oi_CrdBBLKQznAuplIhVBgSxjSIXKGlDGPcCuSjCOEAdE2PRne-wCkom6hBR2SCfztgLBDvxV_bAqlXAaf7t_2ma_7rP1f63fZVcaRxX-rqWtGtkzebXyeaoRr5e9On-spCr7NNNOlpiYi9ukJ81SnJJC0eHf378UpmdLw4zhJEGN5cWOS1OJqYCIad1-QpFYADMHZrBcF2-bt6nKjfwOsFcU1oujqbz4qikk5w2CLElxaNl2iZK0hJmC__CpLxJDs6FObfIel7k9g6hJnEi5omLIwjApPGl9mMIFSWWYERK6h551jIkzRpsdGzRcZjWqM4sRealFfN65HFHO60RQU6leoN87SgQxbv6oZh9SRujkFopLBOx9CVTkQozpRMFJtQEgUq4DoIe2WilIm1MS5kuFaFHHnWXwSjgkx6V2-IYaUIYB5YM87hdC1E3E4Sy4kkCdycr4rUy1dUr-eRrBTwOoTsEvInokeeVJJ6x_nQ4-sSqT3fPXsRDcgn0OP2wO9y7Ry4z0Jk6g2-DrM9nx_Y-uHxz_aDSLUo-n7cy_wVs-myQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+N-acetylcysteine+on+oxidative+stress+biomarkers%2C+depression%2C+and+anxiety+symptoms+in+patients+with+multiple+sclerosis&rft.jtitle=Neuropsychopharmacology+reports&rft.au=Khalatbari+Mohseni%2C+Golsa&rft.au=Hosseini%2C+Seyed+Ahmad&rft.au=Majdinasab%2C+Nastaran&rft.au=Cheraghian%2C+Bahman&rft.date=2023-09-01&rft.eissn=2574-173X&rft_id=info:doi/10.1002%2Fnpr2.12360&rft_id=info%3Apmid%2F37386885&rft.externalDocID=37386885
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-173X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-173X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-173X&client=summon